These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 22349361)

  • 1. Effective blockade of RAAS by combination of aliskiren and olmesartan improves glucose homeostasis, glomerular filtration rate along with renal variables in streptozotocin induced diabetic rats.
    Gandhi S; Srinivasan BP; Akarte AS
    Eur J Pharm Sci; 2012 May; 46(1-2):32-42. PubMed ID: 22349361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aliskiren improves insulin resistance and ameliorates diabetic renal vascular complications in STZ-induced diabetic rats.
    Gandhi S; Srinivasan B; Akarte AS
    J Renin Angiotensin Aldosterone Syst; 2013 Mar; 14(1):3-13. PubMed ID: 22791702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy.
    Bomback AS; Rekhtman Y; Klemmer PJ; Canetta PA; Radhakrishnan J; Appel GB
    J Am Soc Hypertens; 2012; 6(5):338-45. PubMed ID: 22995802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of the renin-angiotensin system improves cerebral microcirculatory perfusion in diabetic hypertensive rats.
    Estato V; Obadia N; Carvalho-Tavares J; Freitas FS; Reis P; Castro-Faria Neto H; Lessa MA; Tibiriçá E
    Microvasc Res; 2013 May; 87():41-9. PubMed ID: 23466285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of angiotensin II receptor antagonist olmesartan on renal hemodynamic variables and vascular structural properties in streptozotocin-induced diabetic rats.
    Song HF; Chen JF; Sun NL; Li HW
    Chin Med J (Engl); 2011 Feb; 124(4):562-7. PubMed ID: 21362282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
    Dalla Vestra M; Simioni N; Masiero A
    Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
    Horký K
    Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of aliskiren to olmesartan ameliorates tubular injury in chronic kidney disease patients partly by reducing proteinuria.
    Nakamura T; Sato E; Amaha M; Kawagoe Y; Maeda S; Yamagishi S
    J Renin Angiotensin Aldosterone Syst; 2012 Mar; 13(1):122-7. PubMed ID: 21946392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-diabetic and renoprotective effects of aliskiren in streptozotocin-induced diabetic nephropathy in female rats.
    Mahfoz AM; El-Latif HA; Ahmed LA; Hassanein NM; Shoka AA
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Dec; 389(12):1315-1324. PubMed ID: 27612855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
    Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
    Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat.
    Erman A; Veksler S; Gafter U; Boner G; Wittenberg C; van Dijk DJ
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):146-51. PubMed ID: 15526251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease.
    Moriyama T; Tsuruta Y; Kojima C; Itabashi M; Sugiura H; Takei T; Ogawa T; Uchida K; Tsuchiya K; Nitta K
    Int Urol Nephrol; 2012 Jun; 44(3):841-5. PubMed ID: 21626132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a triple blockade of the renin-angiotensin-system in recurrent focal segmental glomerulosclerosis after kidney transplantation.
    Freiberger V; Amann K; Heemann U; Frank H
    Transpl Int; 2009 Nov; 22(11):1110-3. PubMed ID: 19497068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism for blockade of angiotensin subtype 1 receptors to lower plasma glucose in streptozotocin-induced diabetic rats.
    Chan P; Liu IM; Tzeng TF; Yang TL; Cheng JT
    Diabetes Obes Metab; 2007 Jan; 9(1):39-49. PubMed ID: 17199717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
    Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
    Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aliskiren improves left ventricular dysfunction and reduces cardiac dilation in Syrian cardiomyopathic hamsters.
    Crespo MJ; Cangiano JL; Altieri PI; Escobales N
    J Cardiovasc Pharmacol; 2012 Jun; 59(6):547-52. PubMed ID: 22370958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of glucose intolerance by combination of pravastatin and olmesartan in type II diabetic KK-A(y) mice.
    Kanno H; Iwai M; Inaba S; Senba I; Nakaoka H; Sone H; Mogi M; Horiuchi M
    Hypertens Res; 2009 Aug; 32(8):706-11. PubMed ID: 19478815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strong suppression of the renin-angiotensin system has a renal-protective effect in hypertensive patients: high-dose ARB with ACE inhibitor (Hawaii) study.
    Ohishi M; Takeya Y; Tatara Y; Yamamoto K; Onishi M; Maekawa Y; Kamide K; Rakugi H
    Hypertens Res; 2010 Nov; 33(11):1150-4. PubMed ID: 20703230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan.
    Iwai M; Li HS; Chen R; Shiuchi T; Wu L; Min LJ; Li JM; Tsuda M; Suzuki J; Tomono Y; Tomochika H; Mogi M; Horiuchi M
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1081-7. PubMed ID: 16990512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.